A deal with Eli Lilly (NYSE:LLY) for exclusive U.S. rights to commercialize tadalafil for pulmonary arterial hypertension last week couldn't prevent United Therapeutics (NASDAQ:UTHR) from getting hosed after its oral treprostinil missed the primary endpoint...

NeurAxon Inc. , Waltham, Mass. Business: Neurology Appointed: Deepa Pakianathan, general partner at Delphi Ventures; and Samuel Wertheimer, principal at OrbiMed Advisors LLC WIR Staff...

NeurAxon (Waltham, Mass.) raised $32 million in a series B round led by new investors Delphi Ventures and OrbiMed Advisors. Existing investors BDC Venture Capital; Genesys Capital; H.I.G. Ventures; NeuroVentures; Ventures West and new investor...

InteKrin Therapeutics Inc. , Palo Alto, Calif. Business: Endocrine, Metabolic Appointed: Jim Healy, general partner at Sofinnova Ventures; Sam Wertheimer, principal at OrbiMed Advisors LLC; and Barry Selick, CEO of Threshold Pharmaceuticals Inc. WIR Staff...

InteKrin (Palo Alto, Calif.) raised $23 million in a venture round led by new investor Sofinnova Ventures. OrbiMed Advisors and Vivo also joined existing investors Asset Management and Sears Capital Management in the round. InteKrin's...

Biodel Inc. , Danbury, Conn. Business: Drug delivery Appointed: David Kroin, cofounder and a managing director of Great Point Partners LLC; Albert Cha, a managing partner of Vivo Ventures; and Samuel Wertheimer, a principal of OrbiMed...